Zykadia (ceritinib)

News alerts, weekly reports and conference planners

Company:

BeiGene, Novartis

Drug class:

ALK inhibitor

Related drugs:

ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A1 - Approval ceritinib Sensitive : A1	ceritinib Sensitive: A1 - Approval ceritinib Sensitive : A1
ROS1 rearrangement	Non Small Cell Lung Cancer	ROS1 rearrangement	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK translocation	Soft Tissue Sarcoma	ALK translocation	Soft Tissue Sarcoma	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2	ceritinib Sensitive: A2 - Guideline ceritinib Sensitive : A2
ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ALK rearrangement	Lung Non-Squamous Non-Small Cell Cancer	ceritinib Sensitive: B - Late Trials ceritinib Sensitive : B	ceritinib Sensitive: B - Late Trials ceritinib Sensitive : B
ALK positive	Lung Adenocarcinoma	ALK positive	Lung Adenocarcinoma	ceritinib Sensitive: C1 - Off-label ceritinib Sensitive : C1	ceritinib Sensitive: C1 - Off-label ceritinib Sensitive : C1
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria ceritinib + ribociclib Sensitive : C2	ceritinib + ribociclib Sensitive: C2 – Inclusion Criteria ceritinib + ribociclib Sensitive : C2
ALK C1156Y	Non Small Cell Lung Cancer	ALK C1156Y	Non Small Cell Lung Cancer	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK fusion	Non Small Cell Lung Cancer	ALK fusion	Non Small Cell Lung Cancer	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK rearrangement	Non-Hodgkin’s Lymphoma	ALK rearrangement	Non-Hodgkin’s Lymphoma	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK F1174C	Non Small Cell Lung Cancer	ALK F1174C	Non Small Cell Lung Cancer	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3
ALK E1129V	Non Small Cell Lung Cancer	ALK E1129V	Non Small Cell Lung Cancer	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK fusion	Colorectal Adenocarcinoma	ALK fusion	Colorectal Adenocarcinoma	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
KRAS mutation	Colorectal Adenocarcinoma	KRAS mutation	Colorectal Adenocarcinoma	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3
ALK I1171T	Non Small Cell Lung Cancer	ALK I1171T	Non Small Cell Lung Cancer	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK G1202R	Non Small Cell Lung Cancer	ALK G1202R	Non Small Cell Lung Cancer	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3
ALK L1196M	Non Small Cell Lung Cancer	ALK L1196M	Non Small Cell Lung Cancer	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK F1174L	Non Small Cell Lung Cancer	ALK F1174L	Non Small Cell Lung Cancer	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3	ceritinib Resistant: C3 – Early Trials ceritinib Resistant : C3
ALK F1245C	Non Small Cell Lung Cancer	ALK F1245C	Non Small Cell Lung Cancer	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	trametinib + ceritinib Sensitive: C3 – Early Trials trametinib + ceritinib Sensitive : C3	trametinib + ceritinib Sensitive: C3 – Early Trials trametinib + ceritinib Sensitive : C3
ALK positive	Non-Hodgkin’s Lymphoma	ALK positive	Non-Hodgkin’s Lymphoma	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
EML4-ALK variant 3	Non Small Cell Lung Cancer	EML4-ALK variant 3	Non Small Cell Lung Cancer	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
EML4-ALK variant 1	Non Small Cell Lung Cancer	EML4-ALK variant 1	Non Small Cell Lung Cancer	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3	ceritinib Sensitive: C3 – Early Trials ceritinib Sensitive : C3
ROS1 rearrangement	Lung Adenocarcinoma	ROS1 rearrangement	Lung Adenocarcinoma	ceritinib Sensitive: C4 – Case Studies ceritinib Sensitive : C4	ceritinib Sensitive: C4 – Case Studies ceritinib Sensitive : C4
ALK G1123S	Non Small Cell Lung Cancer	ALK G1123S	Non Small Cell Lung Cancer	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4
ALK I1171N	Non Small Cell Lung Cancer	ALK I1171N	Non Small Cell Lung Cancer	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4
ALK I1171	Non Small Cell Lung Cancer	ALK I1171	Non Small Cell Lung Cancer	ceritinib Sensitive: C4 – Case Studies ceritinib Sensitive : C4	ceritinib Sensitive: C4 – Case Studies ceritinib Sensitive : C4
STRN-ALK fusion + KRAS G13D	Colorectal Cancer	STRN-ALK fusion + KRAS G13D	Colorectal Cancer	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4
CD74-ROS1 F2004L + PD-L1 expression	Lung Adenocarcinoma	CD74-ROS1 F2004L + PD-L1 expression	Lung Adenocarcinoma	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4	ceritinib Resistant: C4 – Case Studies ceritinib Resistant : C4

Zykadia (ceritinib)

Associations
(67)

Associations
(67)

Zykadia (ceritinib)

Associations(67)

Associations(67)

Associations
(67)

Associations
(67)